Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.
Sukeepaisarnjaroen W, Pham T, Tanwandee T, Nazareth S, Galhenage S, Mollison L, Totten L, Wigg A, Altus R, Colman A, Morales B, Mason S, Jones T, Leembruggen N, Fragomelli V, Sendall C, Guan R, Sutedja D, Tan SS, Dan YY, Lee YM, Luman W, Teo EK, Than YM, Piratvisuth T, Lim SG. Sukeepaisarnjaroen W, et al. Among authors: tanwandee t. World J Gastroenterol. 2015 Jul 28;21(28):8660-9. doi: 10.3748/wjg.v21.i28.8660. World J Gastroenterol. 2015. PMID: 26229408 Free PMC article.
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Flisiak R, Rasenack JW, Kryczka W, Lee CM, Bain VG, Pianko S, Patel K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-2/3 Study Team. Nelson DR, et al. Gastroenterology. 2010 Oct;139(4):1267-76. doi: 10.1053/j.gastro.2010.06.062. Epub 2010 Jul 1. Gastroenterology. 2010. PMID: 20600017 Free PMC article. Clinical Trial.
Findings from a large Asian chronic hepatitis C real-life study.
Lim SG, Phyo WW, Shah SR, Win KM, Hamid S, Piratvisuth T, Tan SS, Dan YY, Lee YM, Ahmed T, Yang WL, Chen KP, Kamat M, Wadhawan M, Madan K, Mehta R, Shukla A, Dhore P, Eapen CE, Abraham P, Tyagi S, Koshy A, Bwa AH, Jafri W, Abid S, Arisar FAQ, Tanwandee T, Yin TP, Tee HP, Hj Md Said RB, Goh KL, Ho SH, Mohamed R, Abu Bakar N. Lim SG, et al. Among authors: tanwandee t. J Viral Hepat. 2018 Dec;25(12):1533-1542. doi: 10.1111/jvh.12989. Epub 2018 Sep 27. J Viral Hepat. 2018. PMID: 30141214
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.
Pianko S, Zeuzem S, Chuang WL, Foster GR, Sarin SK, Flisiak R, Lee CM, Andreone P, Piratvisuth T, Shah S, Sood A, George J, Gould M, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Li Y, Pang M, Yin Y, Feutren G, Jacobson IM; B2202 Study Team. Pianko S, et al. Among authors: tanwandee t. J Viral Hepat. 2012 Sep;19(9):623-34. doi: 10.1111/j.1365-2893.2012.01586.x. Epub 2012 Mar 21. J Viral Hepat. 2012. PMID: 22863266 Clinical Trial.
Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients.
Chuang WL, Jia J, Chan HLY, Han KH, Tanwandee T, Tan D, Chen X, Gane E, Piratvisuth T, Chen L, Xie Q, Sung JJ, Messinger D, Wat C, Bakalos G, Liaw YF. Chuang WL, et al. Among authors: tanwandee t. Aliment Pharmacol Ther. 2018 May;47(9):1306-1316. doi: 10.1111/apt.14595. Epub 2018 Mar 9. Aliment Pharmacol Ther. 2018. PMID: 29520872 Clinical Trial.
Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.
Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, Tan DM, Chen XY, Gane E, Piratvisuth T, Chen L, Xie Q, Sung JJ, Wat C, Bernaards C, Cui Y, Marcellin P. Liaw YF, et al. Among authors: tanwandee t. Hepatology. 2011 Nov;54(5):1591-9. doi: 10.1002/hep.24555. Hepatology. 2011. PMID: 22045673 Clinical Trial.
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, Andreone P, Sood A, Chuang WL, Lee CM, George J, Gould M, Flisiak R, Jacobson IM, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Sola R, Messina I, Yin Y, Cammarata S, Feutren G, Brown KK. Foster GR, et al. Among authors: tanwandee t. J Viral Hepat. 2013 Apr;20(4):e115-23. doi: 10.1111/jvh.12020. Epub 2013 Feb 14. J Viral Hepat. 2013. PMID: 23490379 Clinical Trial.
Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.
Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R, Tanwandee T, Chutaputti A, Yurdaydin C, Bao W, Avila C, Trylesinski A. Chan HL, et al. Among authors: tanwandee t. J Viral Hepat. 2012 Oct;19(10):732-43. doi: 10.1111/j.1365-2893.2012.01600.x. Epub 2012 Mar 15. J Viral Hepat. 2012. PMID: 22967105 Clinical Trial.
122 results